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Low-Grade Inflammation, Metabolic Syndrome and the Risk of 
Chronic Kidney Disease: the 2005 Korean National Health and 
Nutrition Examination Survey
Either chronic inflammation or metabolic syndrome (MetS) is associated with renal 
impairment. This cross-sectional study was designed to investigate the relationship 
between elevated white blood cell (WBC) counts and chronic kidney disease (CKD) stage 3  
or more according to the presence of MetS in adult Koreans. In total, 5,291 subjects  
(≥ 20 yr-old) participating in the 2005 Korean National Health and Nutrition Examination 
were included. CKD stage 3 or more was defined as having an estimated glomerular 
filtration rate below 60 mL/min/1.73 m
2, as calculated using the formula from the 
Modification of Diet in Renal Disease study. The odds ratio (95% confidence interval) for 
CKD stage 3 or more in the highest WBC quartile (≥ 7,200 cells/μL) was 1.70 (1.17-2.39) 
after adjusting for MetS and other covariates, compared with the lowest WBC quartile  
(< 5,100 cells/μL). In subjects with MetS, the prevalence risk for CKD stage 3 or more in 
the highest WBC quartile was 2.25 (1.28-3.95) even after fully adjusting for confounding 
variables. In contrast, this positive association between WBC quartile and CKD stage 3 or 
more disappeared in subjects without MetS. Low-grade inflammation is significantly 
associated with CKD stage 3 or more in subjects with MetS but not in those without MetS.
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INTRODUCTION
Chronic kidney disease (CKD) often progresses to end-stage renal 
disease (ESRD), necessitating renal replacement therapy, and 
the occurrence of which is steadily increasing. According to the 
National Health and Nutrition Examination Survey (NHANES), 
the prevalence of CKD stage 3 or more in the United States was 
10.0% between 1994 and 1998, and it increased to 13.1% between 
1999 and 2004 (1). CKD is known to be associated with cardio-
vascular morbidity and mortality (2). Thus, early identification 
and proper management of CKD can prevent ESRD and associ-
ated mortality.
  Previous studies demonstrated that CKD may be a renal phe-
notype of MetS, which is associated with insulin resistance (3). 
Moreover, chronic low-grade inflammation plays a major role 
in the development of CKD (4). A higher level of C-reactive pro-
tein (CRP) is associated with endothelial injury, impaired vaso-
dilation, and glomerulosclerosis (5). White blood cell (WBC) 
count is also readily available to clinicians as part of complete 
blood count. Recently, WBC count has been known as a useful 
predictor of certain diseases in addition to a marker of infection 
or inflammation. A higher level of WBC count, even within the 
normal range, has been associated with increased morbidity 
and mortality caused by atherosclerotic diseases (6, 7). 
  To date, little is known about whether low-grade inflamma-
tion is related to the risk of CKD, independent of MetS. In the 
present study, we investigated the association between WBC 
count as a nonspecific marker of inflammation and the preva-
lence risk of CKD stage 3 or more in Korean adults compiled in 
the 2005 Korean National Health and Nutrition Examination 
Survey (KNHANES). We further examined the predictive role of 
WBC count on the prevalence of CKD stage 3 or more accord-
ing to the presence of MetS.
MATERIALS AND METHODS
Study sample
This study was based on data obtained from the 2005 Korean 
National Health and Nutrition Examination Survey (KNHANES), 
a cross-sectional and nationally representative survey that was 
conducted by the Ministry of Health and Welfare of the Repub-
lic of Korea in 2005. The target population of the survey was non-Kang H-T, et al.  •  Inflammation, Metabolic Syndrome and Chronic Kidney Disease
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institutionalized civilians in Korea of at least one year of age. 
Sampling units were households that were selected through a 
stratified, multistage, probability-sampling design that was based 
on geographic area, gender, and age from a database of house-
hold registries. There were 246,097 primary sampling units, each 
of which contained approximately 60 households. In total, 600 
sampling frames, comprising 13,345 households from the pri-
mary sampling units, were randomly sampled. Of these, 12,001 
households (89.9%) were included in the study. Weights indi-
cating the probability of being sampled were assigned to each 
participant, enabling the results from this study to represent the 
entire Korean population. Participants completed four parts of 
a questionnaire, composed of a Health Interview Survey, Health 
Behavior Survey, Health Examination Survey, and Nutrition 
Survey. 
  The 2005 KNHANES had 34,145 initial participants. Of the 
25,161 participants who were at least 20 yr old, we excluded sub-
jects (n = 482) who had been diagnosed with any malignancies 
by doctors, as well as subjects (n = 19,326) who did not com-
plete the health interview survey or undergo blood sampling. 
Participants with WBC counts higher than 10,000 cells/μL were 
excluded to rule out the possibility of current infection (n = 62). 
A total of 5,291 individuals (3,856 men and 1,435 women) were 
included in the final analysis.
Data collection
At the time the 2005 KNHANES was conducted, citizens were 
informed that they had been randomly selected as a household 
to voluntarily participate in a nationally representative survey 
conducted by the Korean Government. All citizens were given 
the right to refuse to participate in accordance with the Nation-
al Health Enhancement Act supported by the National Statistics 
Law of Korea. Physical examinations were performed by trained 
investigators following a standardized procedure. Body weight 
and height were measured in light indoor clothing without shoes 
to the nearest 0.1 kg and 0.1 cm, respectively. Waist circumfer-
ence was measured at the narrowest point between the lower 
border of the rib cage and the iliac crest. Body mass index (BMI) 
was calculated as the ratio of weight/height
2 (kg/m
2). Systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) were 
measured in the right arm using a standard mercury sphygmo-
manometer (Baumanometer, Baum, Copiague, NY, USA). The 
average of two systolic and diastolic blood pressure readings, 
which were recorded at an interval of five minutes, was used for 
analysis. Dietary intake was collected using the 24-hr recall 
method. All subjects were instructed to maintain their usual   
dietary habits. Daily calorie intake was calculated with Can-Pro 
2.0, a nutrient intake assessment software program developed 
by the Korean Nutrition Society. After 12 hr of overnight fasting, 
blood samples were obtained from the antecubital veins of the 
study subjects. Fasting plasma glucose, triglyceride (TG), high 
density lipoprotein cholesterol (HDL-C), and creatinine levels 
were measured using a Hitachi 7600-110 chemistry analyzer 
(Hitachi, Tokyo, Japan). WBC counts were quantified by an au-
tomated blood cell counter (ADVIA 120, Bayer, New York, NY, 
USA). 
Definitions of CKD stage 3 or more and metabolic syndrome
We defined CKD stage 3 or more as an estimated glomerular fil-
tration rate (eGFR) below 60 mL/min/1.73 m
2. The eGFR was cal-
culated using the abbreviated equation from the Modification 
of Diet in Renal Disease (MDRD) study: 186.3 × (serum creati- 
nine
-1.154) × (age
-0.203) × 0.742 (if a woman) (8).
  Previously, major organizations including International Dia-
betes Federation and the American Heart Association/National 
Heart, Lung, and Blood Institute issued a harmonizing definition 
of MetS in 2009 (9). According to the harmonizing definition, 
MetS was defined as having three or more of the following crite-
ria: waist circumference  ≥ 90 cm in men and  ≥ 85 cm in wom-
en; systolic blood pressure  ≥ 130 mmHg, diastolic blood pres-
sure  ≥ 85 mmHg, or taking antihypertensive medication; fasting 
plasma glucose  ≥ 100 mg/dL or taking any anti-diabetic medi-
cation; TG level  ≥ 150 mg/dL, or taking any lipid-lowering medi-
cation; HDL-C  < 40 mg/dL in men and  < 50 mg/dL in women 
or taking any lipid-lowering medication.
Statistical analysis
WBC quartiles were categorized as follows: Q1;  < 5,100, Q2; 
5,100-6,000, Q3; 6,100-7,100, and Q4;  ≥ 7,200 cells/μL. With the 
exception of TG, the characteristics of the study sample were 
summarized using either the independent t-test or the one-way 
analysis of variance (ANOVA) for continuous variables and the 
chi-square test for categorical variables. To compare the median 
values of nonparametric variables, such as TG, we used the Mann-
Whitney U test and the Kruskal-Wallis test. We conducted linear 
regression analyses to verify trend analysis. To further evaluate 
the relationship between WBC quartile and CKD stage 3 or more 
in subjects with or without MetS, WBC quartiles were re-cate-
gorized as follows: Q1;  < 5,100, Q2; 5,100-6,000, Q3; 6,100-7,000, 
Q4;  ≥ 7,100 cells/μL in subjects without MetS, and Q1;  < 5,600, 
Q2; 5,600-6,500, Q3; 6,600-8,000, Q4;  ≥ 8,100 cells/μL in subjects 
with MetS. The odds ratios (ORs) and 95% confidence intervals 
(95% CIs) for CKD stage 3 or more were calculated using multi-
variate logistic regression analyses after adjusting for confound-
ing variables across WBC quartiles. All analyses were conducted 
using SAS statistical software, version 9.1 (SAS Institute Inc., Cary, 
NC, USA). All statistical tests were two-sided, and statistical sig-
nificance was determined at P values  < 0.05.
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Seoul, Korea (IRB No. 3-2010-0029). The participants and their 
parents (if applicable) provided written informed consent of 
their participation in the study. The Korea Centers for Disease 
Control and Prevention also obtained written informed consent 
to use blood samples from the participants for further analyses.
RESULTS
The overall prevalence of CKD stage 3 or more is 8.8% (5.6% in 
subjects without MetS versus 17.2% in subjects without MetS) 
after final exclusion. Table 1 lists the characteristics of the 5,291 
subjects according to MetS. The mean or median value of BMI, 
waist circumference, SBP, DBP, fasting plasma glucose, TG, and 
creatinine are significantly higher in subjects with MetS than in 
those without MetS, while serum HDL-C levels and eGFR are 
higher in subjects without MetS than in those with MetS. The 
percentage of current smokers is higher in subjects with MetS, 
while that of regular drinkers is higher in subjects without MetS. 
The mean WBC count is higher in subjects with MetS (6,109 cells/ 
μL in non-MetS group, 6,787 cells/μL in MetS group). 
  Table 2 shows the subject characteristics according to WBC 
count quartile. The mean or median values of BMI, waist circum-
ference, WBC, SBP, DBP, fasting plasma glucose, TG, and creati-
nine increase as WBC quartile increases, while HDL-C decreases 
in accordance with WBC quartile. 
  Table 3 shows the results of the logistic regression analyses 
designed to investigate the relationship between WBC quartile, 
MetS, and CKD stage 3 or more. In comparison with participants 
who are categorized in the first WBC quartile (< 5,100 cells/μL), 
the OR for CKD stage 3 or more of participants who are catego-
rized in the highest WBC quartile (≥ 7,200 cells/μL) is 1.70 (95% 
CI, 1.17-2.39) after adjusting for age, gender, SBP, fasting plasma 
glucose, energy intake, smoking status, alcohol-drinking status, 
BMI, and MetS. Although the OR of MetS for CKD stage 3 or 
more is significant in Model 2, which is fully adjusted except for 
WBC quartile, its significance disappears in Model 4, which is 
fully adjusted including WBC quartile.
  To further evaluate the relationship between WBC quartile 
and CKD stage 3 or more in subjects with or without MetS, we 
conducted multivariate logistic regression analyses that were 
stratified according to MetS (Fig. 1). In subjects with MetS, the 
Table 1. Characteristics of the study subjects 
Parameters Non-MetS MetS P value
No. (men, %) 3,856 (40.4) 1,435 (49.8) < 0.001
Age (yr)   43.8 ± 14.6   55.2 ± 13.5 < 0.001
BMI (m/kg
2) 22.9 ± 2.9 26.1 ± 3.0 < 0.001
WC (cm) 77.8 ± 8.3 89.5 ± 7.6 < 0.001
WBC (cells/µL)   6,109 ± 1,763   6,787 ± 1,936 < 0.001
SBP (mmHg) 114.5 ± 15.6 131.5 ± 17.2 < 0.001
DBP (mmHg) 74.9 ± 9.8   83.9 ± 10.5 < 0.001
FPG (mg/dL)   90.2 ± 16.7 108.6 ± 30.7 < 0.001
TG (mg/dL)* 91.0 (67.0, 123.0) 177.0 (129.0, 240.0) < 0.001
HDL-C (mg/dL)   47.4 ± 10.9 38.8 ± 7.6 < 0.001
Creatinine (mg/dL)   0.97 ± 0.17   1.02 ± 0.23 < 0.001
Current smoker (%)
† 21.3 24.6 < 0.001
Regular drinker (%)
† 75.4 67.4 < 0.001
Energy intake (kcal) 2012.0 ± 829.2 1974.3 ± 849.6 0.174
eGFR (mL/min/1.73 m
2)   77.4 ± 11.8   72.3 ± 12.6 0.002
All data except TG, smoking status, and drinking status are represented as mean ±
standard deviation (SD). Smoking status and drinking status are represented as per-
centages. TG is represented as the median (lower, higher quartile). *P value as deter-
mined by Mann-Whitney U test; 
†P value as determined by chi square test. BMI, body 
mass index; WC, waist circumference; WBC, white blood cell; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TG, triglyceride; HDL-
C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rates.
Table 2. Characteristics according to WBC quartile (cells/µL)
Parameters
Q1 
< 5,100 cells/µL
Q2 
5,100-6,000 cells/µL
Q3 
6,100-7,100 cells/µL
Q4 
≥ 7,200 cells/µL
P value
No. (men, %) 1,520 (25.5) 1,272 (41.0) 1,185 (46.4) 1,314 (61.7)
Age (yr)    48.2 ± 15.3    47.0 ± 14.8    46.2 ± 15.4    46.0 ± 15.0 < 0.001
BMI (m/kg
2)  23.1 ± 3.0  23.7 ± 3.3  23.9 ± 3.4  24.3 ± 3.3 < 0.001
WC (cm)  78.2 ± 9.1  80.7 ± 9.5  81.6 ± 9.7  83.9 ± 9.4 < 0.001
WBC (cells/µL) 4,410 ± 610 5,670 ± 310 6,660 ± 330    8,740 ± 1,530 < 0.001
SBP (mmHg)  116.5 ± 17.6  119.2 ± 17.8  119.8 ± 17.2  121.6 ± 17.8 < 0.001
DBP (mmHg)    75.3 ± 10.3    77.3 ± 10.6    77.7 ± 10.6    79.4 ± 11.2 < 0.001
FPG (mg/dL)    91.4 ± 15.3    94.7 ± 21.8    96.8 ± 27.2    98.6 ± 26.0 < 0.001
TG (mg/dL)* 85.0 (62.0, 121.0) 105.0 (76.0, 147.8) 115.0 (80.0, 175.0) 129.0 (90.0, 199.0) < 0.001
HDL-C (mg/dL)    47.7 ± 11.6    45.2 ± 10.3    44.3 ± 10.2    42.7 ± 10.3 < 0.001
Creatinine (mg/dL)    0.95 ± 0.13    0.98 ± 0.14    1.00 ± 0.24    1.02 ± 0.23 < 0.001
Current smoker (%)
† 10.1 19.5 21.9 39.2 < 0.001
Regular drinker (%)
† 70.9 72.3 73.7 76.5 < 0.001
Energy intake (kcal) 1,919.7 ± 798.6 2,003.8 ± 830.5 1,981.0 ± 787.6 2,115.8 ± 907.9 < 0.001
eGFR (mL/min/1.73 m
2)    74.4 ± 11.6    76.0 ± 11.8    76.2 ± 12.4    77.5 ± 13.0 < 0.001
All data except TG, smoking status, and drinking status are represented as mean ± standard deviation (SD). Smoking status and drinking status are represented as percentages. 
TG is represented as the median (lower, higher quartile). *P value as determined by Kruskal Wallis test; 
†P value as determined by chi square test. BMI, body mass index; WC, 
waist circumference; WBC, white blood cell; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TG, triglyceride; HDL-C, high-density lipo-
protein cholesterol; eGFR, estimated glomerular filtration rates.Kang H-T, et al.  •  Inflammation, Metabolic Syndrome and Chronic Kidney Disease
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risk for CKD stage 3 or more in the highest WBC quartile is 2.25 
(1.28-3.95), even after fully adjusting for confounding variables. 
In contrast, this positive association between CKD stage 3 or 
more and WBC quartile are not found in subjects without MetS. 
DISCUSSION
The major finding in this study is that a higher level of WBC count 
in Korean adults with MetS is strongly associated with the prev-
alence of CKD stage 3 or more, but not in Korean adults without 
MetS. 
  Each component of MetS is strongly associated with the de-
velopment of CKD (10). Abdominal obesity is one of the most 
common risk factors for ESRD and CVD through insulin resis-
tance and inflammatory cytokines secreted by adipose tissue 
(11). High blood pressure and insulin resistance are well-estab-
lished risk factors for CKD in previous studies (12, 13). Dyslipid-
emia also contributes to accelerated development of renal insuf-
ficiency (14). Mesangial cells exposed to lipids are stimulated to 
secrete pro-inflammatory cytokines, such as interleukin-6, tumor 
necrosis factor-α, and transforming growth factor-β, resulting in 
excessive glomerular basement membrane material and glomer-
ulosclerosis (14, 15). Particularly, individuals with high TG and 
low HDL-C levels have a higher risk of renal dysfunction (16).
  Chronic low-grade inflammation is a common risk factor of 
MetS and CKD, as well as CVD (17, 18). Higher levels of inflam-
matory markers such as WBC count and CRP are associated with 
the morbidity and mortality of CKD (18, 19). Chronic low-grade 
inflammation has been identified as an integral part of the patho-
genesis of vascular diseases such as hypertension (20). Vascular 
inflammation plays a crucial role in the development of hyper-
tension through endothelial dysfunction, mediated by a reduced 
availability of nitric oxide (NO) and increased activity of the renin-
angiotensin system (21). Also, a deficiency of the endogenous 
vasodilator, NO, occurs in various stages of CKD and may con-
tribute to the progression of CKD (22, 23). Moreover, various in-
flammatory cytokines are related to the initiation and progres-
sion of CKD (24).
  We show that higher WBC count is associated with the preva-
lence of CKD stage 3 or more, even after adjustment for MetS, 
in addition to the traditional risk factors of CKD. Our results are 
in agreement with previous studies that showed chronic low-
grade inflammation to be a risk factor of CKD (4, 18, 24). In this 
study, MetS is associated with the prevalence of CKD stage 3 or 
more (OR [95% CI] 1.35 [1.00-1.82]) when adjusted only for age, 
gender, SBP, fasting plasma glucose, energy intake, smoking 
status, alcohol-drinking status, and BMI; while the association 
between MetS and CKD stage 3 or more disappears when addi-
tionally adjusted for WBC count. We stratified individuals accord-
ing to the presence of MetS in order to investigate the indepen-
dent effect of WBC count on the prevalence risk of CKD stage 3 
or more after controlling for MetS. Among individuals without 
MetS, WBC count is not associated with the prevalence of CKD 
stage 3 or more. However, in individuals with MetS, the associa-
tion between elevated WBC count and CKD stage 3 or more is 
enhanced (OR [95% CI] 2.25 [1.28-3.95]). In our study, the rela-
tionship between elevated WBC count and CKD stage 3 or more 
is observed only for individuals with MetS for some reason, but 
not for those without MetS. Some studies have shown that inflam-
mation is significantly associated with MetS and its diagnostic 
parameters (11, 17). Probably, after chronic low-grade inflam-
mation initiates subclinical abnormalities of cardiometabolic 
risk factors, leading to MetS, a phenotype of renal impairment 
Table 3. Odds ratio and 95% confidence intervals for chronic kidney disease stage 3 or more according to WBC quartile and metabolic syndrome
Model
WBC counts MetS
Q1 
< 5,100 cells/µL
Q2  
5,100-6,000 cells/µL
Q3  
6,100-7,100 cells/µL
Q4 
≥ 7,200 cells/µL
Non-MetS MetS
Model 1 1 1.32 (0.97-1.80) 1.43 (1.04-1.97) 1.72 (1.25-2.38) 1 1.62 (1.29-2.04)
Model 2 1 1.41 (1.01-1.97) 1.37 (0.96-1.94) 1.73 (1.22-2.47) 1 1.35 (1.00-1.82)
Model 3 1 1.40 (1.00-1.95) 1.34 (0.94-1.90) 1.70 (1.17-2.39)
Model 4 1 1.28 (0.95-1.73)
Model 1, adjusted for age and gender; Model 2, adjusted for SBP, fasting plasma glucose, energy intake, smoking status, alcohol-drinking status, and BMI, additionally to Model 1; 
Model 3, adjusted for metabolic syndrome, additionally to Model 2; Model 4, adjusted for WBC count, additionally to Model.
Fig. 1. Odds ratio for chronic kidney disease stage 3 or more of individuals with or 
without metabolic syndrome, according to WBC quartile. Logistic regression analysis 
model was adjusted for age, gender, SBP, fasting plasma glucose, energy intake, smok-
ing status, alcohol-drinking status, and BMI.
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appears to subsequently develop. Also, co-existence of low-grade 
inflammation and MetS could synergistically affect the deterio-
ration of renal dysfunction. Fakhrzadeh et al. (25) also reported 
that the risk of CKD is increased in subjects with both elevated 
CRP and MetS in an elderly Iranian sample. In that study, sub-
jects with MetS and elevated CRP levels, another inflammatory 
marker, have a 1.71-fold greater risk of CKD stage 3 or more com-
pared to those without MetS and low CRP levels. Our study con-
firms that the co-existence of MetS and chronic low-grade in-
flammation measured according to WBC count is associated 
with the prevalence risk of CKD stage 3 or more.
  There are some study limitations that should be considered 
when interpreting the findings of the present work. First, it is dif-
ficult to determine a causal relationship between a higher WBC 
count and increased risk of CKD stage 3 or more using a cross-
sectional study design. Further prospective research is warranted 
to better understand its causal relationship. Second, we used a 
definition of CKD stage 3 or more as eGFR less than 60 mL per 
min per 1.73 m
2 using the MDRD formula. This eGFR may not 
accurately estimate actual GFR. Furthermore, because the MDRD 
formula was developed using study samples of primarily Euro-
pean descent, an additional estimation of GFR in Koreans may 
be necessary. Third, we did not include individuals with protein-
uria, which may be a phenotype of CKD. However, because the 
urine samples of the 2005 KNHANES were not collected at the 
first void in the morning, it is difficult to obtain quantitative mea-
surements and to control for selection bias. Fourth, the preva-
lence of CKD stage 3 or more seems to be higher than the prev-
alence reported in other studies (26). We could not fully control 
for selection bias in the process of selecting the cases. The mean 
ages of the 5,440 selected participants were significantly older 
than those of the 19,721 excluded participants (47.2 yr vs 45.3 yr). 
Thus, the inclusion of relatively older subjects during the selec-
tion process could have contributed to this higher prevalence of 
CKD stage 3 or more in this study. Finally, because WBC count 
in this study was only measured once, it was not possible to deter-
mine whether an acute episode of infection or chronic inflam-
mation was responsible for the correlation observed. In order to 
minimize the possibility of including participants with active in-
fections, we excluded participants with WBC  ≥ 10,000 cells/μL. 
  In conclusion, low-grade inflammation is significantly asso-
ciated with CKD stage 3 or more in subjects with MetS but not 
in those without MetS.
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